A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Save

Date Added
October 23rd, 2019
PRO Number
Pro00093541
Researcher
Michelle Davis

List of Studies

Silhouette
Keywords
Cancer/Gynecological
Summary

This study is for women with endometrial cancer. The purpose is to find out if adding a new immunotherapy drug to the usual combination of chemotherapy drugs can lower the chance of your endometrial cancer growing or spreading.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Change_preferences

-- OR --

Create_login